AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is currently conducting a Phase III study titled ‘A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma.’ The study aims to evaluate the efficacy and safety of rilvegostomig combined with bevacizumab, with or without tremelimumab, in patients with advanced hepatocellular carcinoma (HCC) who are not eligible for curative or locoregional therapy.
The interventions being tested include the drugs rilvegostomig, bevacizumab, and tremelimumab, all administered as intravenous therapies. These treatments are designed to assess their effectiveness as a first-line treatment option for advanced HCC.
This interventional study is randomized with a parallel assignment model and single masking for outcomes assessors. The primary purpose is treatment-focused, aiming to determine the best therapeutic approach for the target patient group.
The study began on May 6, 2025, with the last update submitted on August 4, 2025. These dates are crucial as they mark the study’s progression and ensure that stakeholders are informed of the latest developments.
The outcome of this study could significantly impact AstraZeneca’s stock performance and investor sentiment, as positive results may enhance the company’s competitive position in the oncology market. Investors should monitor this study, given its potential to influence market dynamics and AstraZeneca’s portfolio.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.